New heart drug EDG-7500 enters Mid-Stage trial for thick heart muscle

NCT ID NCT06347159

Ongoing Disease control Sponsor: Edgewise Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called EDG-7500 in 100 adults with hypertrophic cardiomyopathy, a condition where the heart muscle is abnormally thick. The goal is to check the drug's safety and how it affects heart function. Participants receive single or multiple doses, and researchers measure side effects, drug levels, and changes in heart pressure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EDG-7500 (a drug taken as a liquid or pill)
What this could lead to: If it works, this could point toward a new treatment option for hypertrophic cardiomyopathy, potentially easing symptoms and improving heart function.
What could go wrong: This is an early Phase 2 study with only 100 participants, so results may not apply to everyone. The drug could cause side effects or fail to show meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTROPHIC CARDIOMYOPATHY

Contacts and locations

Show contact details

Locations

Brigham and Womens Hospital

Boston, Massachusetts, 02115, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Duke Health Center Arringdon

Morrisville, North Carolina, 27560, United States
Emory Clinic

Atlanta, Georgia, 30322, United States
Hospital of the University of Pennsylvania (University of Pennsylvania School of Medicine)

Philadelphia, Pennsylvania, 19104, United States
Lahey Hospital and Medical Center

Burlington, Massachusetts, 01805, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Michigan Medicine - Michigan Clinical Research Unit

Ann Arbor, Michigan, 48109, United States
Morristown Medical Center (Atlantic Health System)

Morristown, New Jersey, 07960, United States
NYU Langone Health Medical Center - HCM Program Office (Study open to existing NYU patients only)

New York, New York, 10016, United States
North Shore University Hospital

Manhasset, New York, 11030, United States
Oregon Health & Science University (OHSU)

Portland, Oregon, 97239, United States
Saint Luke's Hospital of Kansas City

Kansas City, Missouri, 64111, United States
Sanger Heart and Vascular Institute

Charlotte, North Carolina, 28204, United States
Stanford University Hospital / Stanford Health Care

Stanford, California, 94305, United States
The Lindner Research Center at Christ Hospital

Cincinnati, Ohio, 45219, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 33612, United States
University of California, San Francisco

San Francisco, California, 94143, United States
University of Virginia Heart and Vascular Center Fontaine

Charlottesville, Virginia, 22903, United States
Virginia Mason Medical Center

Seattle, Washington, 98101, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.